Abstract
Neonatal units in the UK are beginning to use Vapotherm as a means of providing respiratory support. This device reportedly allows the delivery of high flows of gas at body temperature with close to 100 per cent relative humidity. Evidence from the literature and from UK neonatal units suggests that Vapotherm may be an effective and well-tolerated method of providing babies with respiratory support. It has a number of advantages over therapies such as nasal continuous positive airway pressure, including a reduction in the number of ventilator days and reduced nasal trauma. It is reported to be better tolerated than other forms of non-invasive respiratory therapy. There is some evidence to show that weight gain is improved on Vapotherm and that oral feeding can be introduced earlier. Further research is required, especially into the methods of weaning Vapotherm and, as with all neonatal treatments, the long-term effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
